Wilmington Eye Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma

Wilmington Eye announced the availability of iDose® TR (travoprost intraocular implant) 75 mcg, an FDA-approved treatment for managing eye pressure in ocular hypertension and open-angle glaucoma patients. This new therapy provides long-term, continuous drug delivery directly inside the eye.

Dr. Robert van der Vaart, a specialist at Wilmington Eye, highlighted the benefits of iDose TR over traditional prescription eye drops, which are often difficult to administer and can cause side effects. iDose TR aims to address these issues by offering a hands-free alternative to manage eye pressure effectively.

Manufactured by Glaukos, iDose TR reduces eye pressure by releasing medication commonly used in eye drops. In clinical trials, 80% of patients did not need additional eye drops for 12 months post-administration. It is particularly beneficial for patients struggling with daily medication adherence.

CEO Kathy Erickson emphasized Wilmington Eye's commitment to advanced treatments, noting that iDose TR represents a significant advancement in glaucoma care.

While effective, iDose TR can cause side effects such as increased eye pressure, iris inflammation, dry eye, and vision changes. Patients are advised to consult with their doctor for more safety information.